Drugs and patents in ATC class M04 - ANTIGOUT PREPARATIONS

Last updated: February 19, 2026

What is the Current Market Size and Projected Growth for Antigout Preparations?

The global market for antigout preparations is substantial and exhibits consistent growth, driven by an increasing prevalence of gout worldwide. Gout, a form of inflammatory arthritis characterized by hyperuricemia, affects millions globally. Rising obesity rates, dietary shifts, and an aging population are primary contributors to this increasing incidence.

In 2022, the global gout therapeutics market was valued at approximately $3.8 billion. Projections indicate a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030, with the market expected to reach an estimated $6.1 billion by 2030. This growth trajectory is supported by the ongoing development of novel therapeutic agents and an expanding understanding of gout's pathophysiology. The primary market segments include urate-lowering drugs (ULTs) and anti-inflammatory agents used to manage acute gout attacks. ULTs, which include xanthine oxidase inhibitors (XOIs) and uricosuric agents, constitute the larger segment of the market.

Which Patented Molecules Dominate the Antigout Preparations Market?

The antigout preparation market is largely defined by a few key patented molecules, with significant revenue generated by both established and emerging therapies.

Febuxostat: This selective xanthine oxidase inhibitor is a cornerstone of gout treatment. Its patent protection has been a significant driver of market value for originator companies. Key patents surrounding febuxostat's composition of matter and methods of use have been critical. While some foundational patents have expired in major markets, leading to generic competition, new patents related to specific formulations, dosages, or combinations continue to emerge. For example, patents covering extended-release formulations aim to improve patient compliance and therapeutic outcomes.
Lesinurad: A selective URAT1 inhibitor, lesinurad is used in combination with XOIs for the treatment of hyperuricemia associated with gout. Its patent portfolio includes composition of matter patents and specific indication patents. The exclusivity provided by these patents has allowed for premium pricing and market positioning.
Colchicine: Although an older drug, colchicine remains important for managing acute gout flares. While its original composition of matter patents have long expired, new patents may cover purified forms, specific salt forms, or novel delivery systems designed to mitigate its side effect profile.
Pegloticase: This recombinant uricase enzyme is a potent urate-lowering therapy for chronic, refractory gout. Its complex biological nature means that patents often cover the gene sequences, expression systems, purification methods, and specific formulations. The high cost of biologicals like pegloticase necessitates strong patent protection to recoup development expenses.

What is the Patent Expiration Timeline for Key Antigout Molecules?

The patent expiration timeline is a critical factor for market dynamics, signaling the potential for generic entry and subsequent price erosion.

Molecule	Primary Patent Expiration (Approximate)	Market Impact
Febuxostat	2020-2025 (Major Markets)	Increasing generic competition, leading to price declines and market share shifts.
Lesinurad	2029-2032 (Composition of Matter)	Continued market exclusivity for originator, with limited generic pressure until expiration.
Colchicine	Expired (Composition of Matter)	Generic availability, with potential for new patents on improved formulations.
Pegloticase	2028-2030 (Biological Patents)	Extended market exclusivity due to the complexity of biological patents and potential for biosimilar competition.

Note: Expiration dates can vary significantly based on country, patent type, and legal challenges. This table provides approximate general timelines for major markets.

Who are the Key Patent Holders in the Antigout Preparations Space?

Several pharmaceutical companies hold significant patent portfolios related to antigout preparations, influencing market exclusivity and innovation.

Takeda Pharmaceutical Company: Holds key patents for febuxostat (Uloric®).
Ardea Biosciences (AstraZeneca): Previously held patents for lesinurad (Zurampic®).
H. Lundbeck A/S: Holds patents for colchicine formulations.
BridgeBio Pharma: Developing novel therapies, including FGFR inhibitors for gout, with pending patent applications.
Ironwood Pharmaceuticals: Has explored patented combination therapies.
Numerous Generic Manufacturers: Companies like Teva Pharmaceuticals, Mylan N.V., and others are actively involved in challenging existing patents and developing generic versions of antigout medications.

What are the Emerging Patent Trends in Antigout Preparations?

Patent filings in the antigout space are shifting towards novel mechanisms of action, improved drug delivery, and combination therapies, reflecting ongoing research and development efforts.

Novel Mechanisms of Action:
- Adenosine Triphosphate (ATP)-Sensitive Potassium Channel Modulators: Research into targeting potassium channels to reduce urate reabsorption.
- Inhibitors of URATv1 (Urate Transporter Variant 1): Exploring new transporters involved in urate homeostasis.
- Janus Kinase (JAK) Inhibitors: Investigated for their anti-inflammatory effects in gout flares.
- N-acylphosphatidylinositol-Specific Phospholipase C (NIPPC) Inhibitors: Emerging targets for modulating inflammatory pathways.
Advanced Drug Delivery Systems:
- Extended-Release Formulations: Patents focusing on sustained release of existing molecules like febuxostat to improve patient adherence and reduce dosing frequency.
- Nanoparticle Formulations: Exploration of nano-sized drug carriers for enhanced bioavailability and targeted delivery of urate-lowering agents.
Combination Therapies:
- Patents are being filed for synergistic combinations of existing drugs (e.g., XOIs with uricosurics) or novel drug combinations addressing both hyperuricemia and inflammation.
Biologics and Biosimilars:
- While pegloticase is a current biologic, ongoing research into novel biological targets for gout may lead to new patent filings. The potential for biosimilars of existing biologics also represents an area of patent activity.
Repurposing of Existing Drugs:
- Identifying new therapeutic uses for established drugs through patent filings, potentially for gout management.

What is the Competitive Landscape Shaped by Patent Strategy?

The patent landscape directly dictates the competitive dynamics within the antigout preparations market.

Exclusivity and Market Dominance: Strong, unexpired composition of matter patents grant originators market exclusivity, allowing them to set premium prices and capture significant market share. For instance, the period of patent protection for febuxostat by Takeda enabled substantial revenue generation.
Generic Entry and Price Erosion: Patent expiration, particularly for small molecules, inevitably leads to the entry of generic competitors. This intensifies competition, drives down prices, and shifts market share away from originators. The market for older antigout drugs like allopurinol and even febuxostat in some regions demonstrates this effect.
"Patent Thickets" and Litigation: Companies often employ strategies to extend market exclusivity beyond the initial composition of matter patents. This involves filing numerous secondary patents covering manufacturing processes, polymorphs, formulations, and methods of use. These "patent thickets" can deter generic manufacturers or lead to costly patent litigation. For example, disputes over the patentability of specific febuxostat formulations have occurred.
Innovation and Differentiation: The threat of generic competition incentivizes originator companies to invest in research and development of next-generation therapies. Patenting novel mechanisms of action or superior drug delivery systems allows companies to differentiate their products and maintain a competitive edge. BridgeBio Pharma's focus on novel targets exemplifies this strategy.
Biosimilar Development: For biological drugs like pegloticase, the patent landscape influences the development and launch of biosimilars. Patent strategies in this area are complex, involving protection of the manufacturing process, specific variants, and therapeutic uses.

What are the Regulatory Considerations Influencing Patent Strategy?

Regulatory pathways for drug approval and patent protection are intertwined and critically influence market entry and commercialization.

Data Exclusivity: In addition to patent protection, regulatory bodies grant periods of data exclusivity upon drug approval. This period prevents generic or biosimilar manufacturers from relying on the innovator's clinical trial data for their own applications, regardless of patent status. This offers a supplementary layer of market protection.
Orphan Drug Designation: For drugs targeting rare conditions or specific patient populations within gout (e.g., very severe, refractory cases), orphan drug designation can provide extended market exclusivity (typically 7 years in the US, 10 years in the EU) beyond patent life.
Post-Grant Review and Inter Partes Review (IPR): In jurisdictions like the United States, mechanisms such as Post-Grant Review and IPR allow third parties to challenge the validity of granted patents. This has become a significant strategy for generic companies to accelerate market entry.
Settlement Agreements: Patent litigation between originators and generic companies often results in settlement agreements. These agreements may include provisions for delayed generic entry in exchange for licensing or other considerations. Such agreements are subject to regulatory scrutiny.
Labeling Exclusivity: Patents may also cover specific indications or patient populations. Regulatory approval for new uses of a patented drug can extend effective market protection for that specific application.

Key Takeaways

The antigout preparations market is projected for robust growth, reaching an estimated $6.1 billion by 2030, driven by rising gout prevalence.
Febuxostat, lesinurad, and pegloticase are key patented molecules contributing significantly to current market value, with their patent expiration timelines influencing future competition.
Takeda Pharmaceutical Company and Ardea Biosciences (AstraZeneca) are prominent patent holders for blockbuster antigout drugs.
Emerging patent trends focus on novel mechanisms of action (e.g., FGFR inhibitors), advanced drug delivery systems, and combination therapies.
Patent strategy is central to market competition, dictating exclusivity, enabling generic entry, and driving innovation.
Regulatory considerations, including data exclusivity and post-grant review, play a crucial role in shaping the patent landscape and market access for antigout preparations.

FAQs

What is the typical duration of patent protection for small molecule antigout drugs? Typically, composition of matter patents for small molecule drugs have an initial term of 20 years from the filing date. However, extensions and supplementary protection certificates can sometimes extend this period in specific markets.
How do biosimilars of antigout biologics differ from generics of small molecules? Biosimilars are highly similar to their reference biologic products, but due to their complex biological nature, they cannot be identical. Generic drugs, conversely, are exact copies of small molecule drugs. The regulatory approval process and patent strategies for biosimilars are more intricate.
What is the significance of "evergreening" in antigout drug patents? "Evergreening" refers to strategies used by pharmaceutical companies to extend patent protection beyond the initial expiration. This can involve obtaining new patents for minor modifications like new formulations, dosages, or delivery methods. This practice aims to prolong market exclusivity and revenue streams.
Are there any specific patents that have been successfully challenged and led to early generic entry for major antigout drugs? Yes, numerous patents for drugs like febuxostat have faced challenges from generic manufacturers through mechanisms like Inter Partes Review, sometimes leading to earlier-than-expected generic entry in certain jurisdictions. Specific outcomes depend on the legal jurisdiction and the patents in question.
What role does intellectual property play in attracting investment for antigout R&D? A strong and defensible patent portfolio is essential for attracting investment in antigout research and development. Investors rely on the promise of market exclusivity, protected by patents, to ensure a return on investment for the significant costs associated with drug discovery and clinical trials.

Citations

[1] Global Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023-2030. Grand View Research. Retrieved from https://www.grandviewresearch.com/industry-analysis/gout-therapeutics-market [2] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ [3] European Medicines Agency. (n.d.). Medicines. Retrieved from https://www.ema.europa.eu/en/medicines

Drugs in ATC Class M04

Subclasses in ATC: M04 - ANTIGOUT PREPARATIONS

Antigout Preparations (ATC M04): Patent Landscape and Market Dynamics